This Roche business report presents the course of business throughout the respective business year. The 2023 report complies with the disclosure requirement for corporate entities and generally includes the balance sheet, the annual statement of the comp
culture and daily operations and to report on the results achieved each year.We published our first Communication on ProgressCoPin the first quarter of 2022 and will oursecond CoP in the first quarter of2023.External assuranceSome selected key figures of our non-financial reporting for the year ...
0 reviews This school does not have enough reviews yet.Click hereto submit your review. Undergraduate data are based on the 2023 school year.
9Liu H, et al. Six-month Crovalimab Extension in the Phase III COMMODORE 3 Study: Updated Efficacy and Safety Results in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria. Poster presentation at European Hematology Assoc...
SAN DIEGO, Aug. 29, 2023 /PRNewswire/ --Halozyme Therapeutics, Inc.(NASDAQ: HALO) (“Halozyme”) today announced the approval of Roche’s Tecentriq®SC (atezolizumab), using Halozyme’s ENHANZE®drug delivery technology, by the Medicines and Healthcare Products Regulat...
香港朱羅氏生物科技有限公司是一家香港公司,註冊於灣仔,坐落於駱克道上,该司已经成立了5年1个月25天。您可在線瀏覽香港朱羅氏生物科技有限公司的英文名稱、中文名稱、歷史名稱、注冊編號、成立日期、改名日期、董事等企業信息,並可為你提供“香港朱羅氏生物科技有限公司”的信用報告服務。
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation se
By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission on March...
ALK+ NSCLC: US/EU approval • Inavolisib in 1L PIK3CA-mut HR+ BC: US/EU filing • Ph III (SKYSCRAPER-01) tiragolumab + Tecentriq in 1L PD-L1+ NSCLC final OS results expected in H2 2024 Definition of Pharmaceuticals TA split used in the FY 2023 Financial Report vs. IR ...
Barbara Schaedler, Head of Group Communications and Member of the Enlarged CECBoris Zaïtra, Head of Corporate Business Development and Member of the Enlarged CECClaudia Böckstiegel, General Counsel and Member of the Enlarged CECLevi Garraway, Head of Global Product Development and CMO and ...